The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE2 signalling in colorectal adenoma cells

Oncogene

Volumn 29, Issue 23, 2010, Pages 3398-3410

  Greenhough, A ^a   Wallam, C A ^a   Hicks, D J ^a   Moorghen, M ^b   Williams, A C ^a   Paraskeva, C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Apoptosis; Bim; Colorectal cancer; COX 2; ERK; PGE2

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; COLORECTAL ADENOMA; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOMA; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE PROGRESSION; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 77953478344     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.94     Document Type: Article

References (74)

1. Balmanno K. Differ Death Cell Pathway. Erk1/2 The By Signalling Survival Cell Tumour (2009). C.Sj. 16 368-377.
2. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM et al. (1995). Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55: 1811-1816.
3. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F et al. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286: 1735-1738.
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
5. Brown JR, DuBois RN. (2005). COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855.
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
7. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ et al. (2008). Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 21: 534-544.
8. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510.
9. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365.
10. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. (1998). Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686.
11. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D et al. (2006). Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66: 3106-3113.
12. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
13. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. (2001). BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711.
14. Clemo NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G et al. (2008). BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis 29: 849-857.
15. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ et al. (2007). BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4: 1669-1679, discussion 1680.
16. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. (2008). Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118: 3651-3659.
17. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. (2007). Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4: 1681-1689, discussion 1690.
18. Crew TE, Elder DJ, Paraskeva C. (2000). A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 21: 69-77.
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
20. Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN et al. (2009). betaTrCP-and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 33: 109-116.
21. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. (2000). Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204.
22. Egle A, Harris AW, Bouillet P, Cory S. (2004). Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101: 6164-6169.
23. Elder DJ, Baker JA, Banu NA, Moorghen M, Paraskeva C. (2002). Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 198: 428-434.
24. Elder DJ, Hague A, Hicks DJ, Paraskeva C. (1996). Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. Cancer Res 56: 2273-2276.
25. Elder DJ, Paraskeva C. (1998). COX-2 inhibitors for colorectal cancer. Nat Med 4: 392-393.
26. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS et al. (2005). Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expres-sing cells. Oncogene 24: 2317-2329.
27. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R et al. (2007). ERK1/2-dependent phosphor-ylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 26: 2856-2867.
28. Gallenne T, Gautier F, Oliver L, Hervouet E, Noel B, Hickman JA et al. (2009). Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol 185: 279-290.
29. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG et al. (2008). BAX activation is initiated at a novel interaction site. Nature 455: 1076-1081.
30. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL et al. (2009). Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136: 1136-1147.
31. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X et al. (2007). Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adeno-carcinomas. PLoS Med 4: e294.
32. Greenhough A, Patsos HA, Williams AC, Paraskeva C. (2007). The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 121: 2172-2180.
33. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C et al. (2009). The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvir-onment. Carcinogenesis 30: 377-386.
34. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. (2001). COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744.
35. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. (1994). BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 9: 3367-3370.
36. Hall PA, Coates PJ, Ansari B, Hopwood D. (1994). Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 107(Part 12): 3569-3577.
37. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
38. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L et al. (1996). Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52: 237-245.
39. Hawcroft G, Ko CW, Hull MA. (2007). Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 26: 3006-3019.
40. Johnstone RW, Ruefli AA, Lowe SW. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164.
41. Kaidi A, Qualtrough D, Williams AC, Paraskeva C. (2006). Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66: 6683-6691.
42. Kaidi A, Williams AC, Paraskeva C. (2007). Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210-217.
43. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. (1996). Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422-2427.
44. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. (2006). Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103: 14907-14912.
45. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192.
46. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. (2003). Activation of the ERK1/2 signaling pathway promotes phosphor-ylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816.
47. Ley R, Ewings KE, Hadfield K, Cook SJ. (2005). Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 12: 1008-1014.
48. Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ. (2004). Extracellular signal-regulated kinases 1/2 are serum-stimulated 'Bim(EL) kinases' that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 279: 8837-8847.
49. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B et al. (2008). Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135: 1074-1084.
50. Loveridge CJ, MacDonald AD, Thoms HC, Dunlop MG, Stark LA. (2008). The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene 27: 2648-2655.
51. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G et al. (2003). Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22: 6785-6793.
52. Nishihara H, Kizaka-Kondoh S, Insel PA, Eckmann L. (2003). Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 100: 8921-8926.
53. O'Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, Bath ML et al. (2000). The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol 157: 449-461.
54. Paraskeva C, Finerty S, Mountford RA, Powell SC. (1989). Specific cytogenetic abnormalities in two new human colorectal adenoma-derived epithelial cell lines. Cancer Res 49: 1282-1286.
55. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM et al. (2004). Colon carcinoma cell growth is associated with prostaglan-din E2/EP4 receptor-evoked ERK activation. J Biol Chem 279: 29797-29804.
56. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND et al. (2007). ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129: 1337-1349.
57. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J et al. (2003). Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 5: 733-740.
58. Rice PL, Beard KS, Driggers LJ, Ahnen DJ. (2004). Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res 64: 8148-8151.
59. Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES et al. (2007). Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci USA 104: 3787-3792.
60. Sheng H, Shao J, Washington MK, DuBois RN. (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081.
61. Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ et al. (2008). Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 14: 5810-5818.
62. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A et al. (2005). Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24: 1348-1358.
63. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P et al. (2005). Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7: 227-238.
64. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. (2005). Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65: 1822-1829.
65. Wang D, Dubois RN. (2009). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788.
66. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B et al. (2004). Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295.
67. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R et al. (2003). Activation of ERK1/2 by deltaRaf-1:ER&z.ast;represses Bim expression independently of the JNK or PI3K pathways. Oncogene 22: 1281-1293.
68. Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M et al. (2008). Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 27: 7150-7161.
69. Williams AC, Harper SJ, Paraskeva C. (1990). Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. Cancer Res 50: 4724-4730.
70. Williams AC, Smartt H, AM HZ, Macfarlane M, Paraskeva C, Collard TJ. (2007). Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human color-ectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ 14: 137-145.
71. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
72. Yang SY, Sales KM, Fuller B, Seifalian AM, Winslet MC. (2009). Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 15: 225-233.
73. Youle RJ, Strasser A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
74. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S et al. (2007). Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26: 7038-7048.